AI assistant
STADA Arzneimittel AG Board/Management Information 2015
412_rns_2015-11-11_d2f52e3d-0413-4309-bb35-841ec7b2b445.html
Board/Management Information
Open in viewerOpens in your device viewer
News Details
Corporate | 11 November 2015 11:52
STADA Arzneimittel AG: Appointment of Helmut Kraft as Chief Financial Officer extended
DGAP-News: STADA Arzneimittel AG / Key word(s): Contract
2015-11-11 / 11:52
Press release
STADA: Appointment of Helmut Kraft as Chief Financial Officer extended
Bad Vilbel, November 11, 2015 – On November 11, 2015, the Supervisory Board of STADA Arzneimittel AG extended the appointment of Helmut Kraft, Chief Financial Officer, by one year until December 31, 2019. Kraft has been a Member of STADA’s Executive Board since 2010. His previous contract would have ended on December 31, 2018. In addition to the area of Finance (Controlling and Accounting, Treasury and Taxes) Kraft is also responsible for Internal Audit, IT, Business Transformation and Investor Relations within the Executive Board.
“I’m very pleased to have the opportunity, as a result of the extension of the contract, to contribute to STADA’s further successful development. This includes ensuring the sustainable financial stability with which we will further accelerate the expansion strategy of the Group”, says Kraft with regard to the perspective of the continuation of his activities on the STADA Executive Board.
Overall, STADA’s Executive Board continues to consist of Hartmut Retzlaff, Chairman, Helmut Kraft, Chief Financial Officer, and Dr. Matthias Wiedenfels, Chief Business Development & Central Services Officer.
Additional information for analysts:
STADA Arzneimittel AG / Investor Relations / Stadastraße 2-18 / 61118 Bad Vilbel – Germany /
Phone: +49 (0) 6101 603-113 / Fax: +49 (0) 6101 603-215 / E-mail: [email protected]
Additional information for journalists:
STADA Arzneimittel AG / Media Relations / Stadastraße 2-18 / 61118 Bad Vilbel – Germany /
Phone: +49 (0) 6101 603-165 / Fax: +49 (0) 6101 603-215 / E-mail: [email protected]
Or visit us in the Internet at http://www.stada.com .
2015-11-11 Dissemination of a Corporate News, transmitted by DGAP – a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
| Language: | English |
| Company: | STADA Arzneimittel AG |
| Stadastraße 2-18 | |
| 61118 Bad Vilbel | |
| Germany | |
| Phone: | +49 (0)6101 603- 113 |
| Fax: | +49 (0)6101 603- 506 |
| E-mail: | [email protected] |
| Internet: | www.stada.de |
| ISIN: | DE0007251803, DE0007251845, |
| WKN: | 725180, 725184, |
| Indices: | MDAX |
| Listed: | Regulated Market in Dusseldorf, Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Hamburg, Hanover, Munich, Stuttgart |
| End of News | DGAP News Service |
| - - - |
| 411717 2015-11-11 |